PL1894567T3 - Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanie - Google Patents
Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanieInfo
- Publication number
- PL1894567T3 PL1894567T3 PL06747114T PL06747114T PL1894567T3 PL 1894567 T3 PL1894567 T3 PL 1894567T3 PL 06747114 T PL06747114 T PL 06747114T PL 06747114 T PL06747114 T PL 06747114T PL 1894567 T3 PL1894567 T3 PL 1894567T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical agents
- concomitant pharmaceutical
- concomitant
- agents
- pharmaceutical
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005164213 | 2005-06-03 | ||
| EP06747114A EP1894567B1 (en) | 2005-06-03 | 2006-06-02 | Concomitant pharmaceutical agents and use thereof |
| PCT/JP2006/311073 WO2006129785A1 (ja) | 2005-06-03 | 2006-06-02 | 医薬の併用およびその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1894567T3 true PL1894567T3 (pl) | 2013-01-31 |
Family
ID=37481712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06747114T PL1894567T3 (pl) | 2005-06-03 | 2006-06-02 | Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanie |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8754032B2 (pl) |
| EP (1) | EP1894567B1 (pl) |
| JP (2) | JP5586829B2 (pl) |
| KR (2) | KR20130103631A (pl) |
| CN (2) | CN102210865A (pl) |
| BR (1) | BRPI0611074A2 (pl) |
| CA (1) | CA2610361C (pl) |
| DK (1) | DK1894567T3 (pl) |
| ES (1) | ES2390231T3 (pl) |
| PL (1) | PL1894567T3 (pl) |
| PT (1) | PT1894567E (pl) |
| WO (1) | WO2006129785A1 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003790B2 (en) | 2005-02-18 | 2011-08-23 | Mitsubishi Tanabe Pharma Corporation | Salt of proline derivative, solvate thereof, and production method thereof |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| WO2009128360A1 (ja) * | 2008-04-18 | 2009-10-22 | 大日本住友製薬株式会社 | 糖尿病治療剤 |
| ES2507491T3 (es) * | 2008-05-14 | 2014-10-15 | Sanwa Kagaku Kenkyusho Co., Ltd | Preparación farmacéutica que comprende un inhibidor de DPP-IV y otros agentes terapéuticos de la diabetes en forma concomitante o combinada |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) * | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| EA031225B1 (ru) | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы дпп-4 для заживления ран |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| JP2012517977A (ja) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| BR112012011237A2 (pt) * | 2009-11-13 | 2019-09-24 | Univ Tokyo | agente terapêutico e profilático para diabetes |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CN103619334A (zh) * | 2011-01-19 | 2014-03-05 | 朱红文 | 噻唑烷衍生物和其治疗用途 |
| CN102793716B (zh) * | 2011-05-24 | 2014-06-04 | 北大方正集团有限公司 | 脂族胺聚合物的用途及其药物组合物和制备方法 |
| US9132191B2 (en) * | 2011-06-08 | 2015-09-15 | Yale University | Compositions and methods of preventing or ameliorating abnormal thrombus formation and cardiovascular disease |
| EP2849754B1 (en) | 2012-05-14 | 2022-09-14 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| RU2654069C2 (ru) * | 2012-08-31 | 2018-05-16 | Гленмарк Фармасьютикалс Лимитед | Способ получения тенелиглиптина |
| KR101526825B1 (ko) * | 2014-12-23 | 2015-06-08 | 주식회사 한독 | 당뇨병 치료용 약제학적 조성물 |
| CN106880643A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 用于治疗糖尿病的联合用药及药物组合物 |
| WO2017198177A1 (en) * | 2016-05-20 | 2017-11-23 | Center Laboratories, Inc. | Method of treating hyperglycemia |
| JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
| KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
| CN114053281B (zh) * | 2020-08-10 | 2025-05-27 | 成都文鼎科技发展有限公司 | 治疗慢性肾病的方法和药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1741445E (pt) * | 2000-01-21 | 2013-11-11 | Novartis Ag | Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US7078397B2 (en) * | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| KR100817378B1 (ko) * | 2000-08-10 | 2008-03-27 | 미츠비시 웰파마 가부시키가이샤 | 프롤린 유도체 및 그 의약 용도 |
| EP1426366A4 (en) * | 2001-09-14 | 2004-12-08 | Mitsubishi Pharma Corp | THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE |
| US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
-
2006
- 2006-06-02 KR KR1020137022776A patent/KR20130103631A/ko not_active Ceased
- 2006-06-02 KR KR1020077030599A patent/KR101438234B1/ko active Active
- 2006-06-02 ES ES06747114T patent/ES2390231T3/es active Active
- 2006-06-02 BR BRPI0611074-6A patent/BRPI0611074A2/pt active Search and Examination
- 2006-06-02 JP JP2007519080A patent/JP5586829B2/ja active Active
- 2006-06-02 WO PCT/JP2006/311073 patent/WO2006129785A1/ja not_active Ceased
- 2006-06-02 EP EP06747114A patent/EP1894567B1/en not_active Not-in-force
- 2006-06-02 CN CN2011100829567A patent/CN102210865A/zh active Pending
- 2006-06-02 PT PT06747114T patent/PT1894567E/pt unknown
- 2006-06-02 CN CN2006800188067A patent/CN101237870B/zh active Active
- 2006-06-02 PL PL06747114T patent/PL1894567T3/pl unknown
- 2006-06-02 US US11/916,356 patent/US8754032B2/en not_active Expired - Fee Related
- 2006-06-02 DK DK06747114.4T patent/DK1894567T3/da active
- 2006-06-02 CA CA2610361A patent/CA2610361C/en not_active Expired - Fee Related
-
2012
- 2012-09-12 JP JP2012201011A patent/JP2013032359A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1894567B1 (en) | 2012-08-15 |
| US8754032B2 (en) | 2014-06-17 |
| JP2013032359A (ja) | 2013-02-14 |
| CN101237870A (zh) | 2008-08-06 |
| CN102210865A (zh) | 2011-10-12 |
| WO2006129785A1 (ja) | 2006-12-07 |
| DK1894567T3 (da) | 2012-11-19 |
| JP5586829B2 (ja) | 2014-09-10 |
| KR101438234B1 (ko) | 2014-09-04 |
| CA2610361C (en) | 2013-11-26 |
| CA2610361A1 (en) | 2006-12-07 |
| KR20130103631A (ko) | 2013-09-23 |
| US20090082256A1 (en) | 2009-03-26 |
| KR20080040643A (ko) | 2008-05-08 |
| EP1894567A4 (en) | 2009-05-20 |
| PT1894567E (pt) | 2012-11-21 |
| JPWO2006129785A1 (ja) | 2009-01-08 |
| CN101237870B (zh) | 2011-05-25 |
| ES2390231T3 (es) | 2012-11-07 |
| EP1894567A1 (en) | 2008-03-05 |
| BRPI0611074A2 (pt) | 2010-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1894567T3 (pl) | Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanie | |
| IL191160A0 (en) | Pyridopyrazine derivatives and use thereof | |
| GB0413730D0 (en) | A pharmaceutical composition and its use | |
| GB0413729D0 (en) | A pharmaceutical composition and its use | |
| EP1857489A4 (en) | MICROPARTICLE AND PHARMACEUTICAL COMPOSITION | |
| IL186616A (en) | Spyro-oxa-indoles and their use as drugs | |
| IL189781A0 (en) | Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same | |
| GB0419849D0 (en) | Pharmaceutical combination | |
| IL203898A0 (en) | Cdca1 peptide and pharmaceutical agent comprising the same | |
| GB0512940D0 (en) | Compounds and their use | |
| AP2008004533A0 (en) | Pharmaceutical combination | |
| EP1890677A4 (en) | PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
| IL189252A0 (en) | Dihydroxyanthraquinones and their use | |
| GB0516069D0 (en) | Pharmaceutical and use thereof | |
| GB0520743D0 (en) | Compounds and their use | |
| PT2380575E (pt) | Acetato de eslicarbazepina e utilização | |
| AP1994A (en) | An antimycobacterial pharmaceutical composition | |
| EP1884510A4 (en) | N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| IL186851A0 (en) | Styrylsulfonamides, their manufacture and use as pharmaceutical agents | |
| ZA200804666B (en) | Pharmaceutical combination | |
| EP1852117A4 (en) | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN | |
| EP1786415A4 (en) | METABOLISM MODULATION AGENTS AND USES THEREOF | |
| IL185575A0 (en) | Benzoxazocines and their therapeutic use | |
| IL187419A0 (en) | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | |
| IL189827A0 (en) | Pharmaceutical dosage forms and compositions comprising lecoztan |